Northwire Canada EditionFriday, October 16, 2026
Sign inSubscribe
Northwire
⌕
GOLD 4186.90 +0.4% SILVER 57.40 +0.4% COPPER 6.59 +0.5% OIL 96.85 −1.1% PALLADIUM 1120.25 −0.7% MON 0.385 −6.1% OMI 0.255 +2.0% BUFF 0.800 +2.6% FEO 0.670 +3.1% LIB 0.700 −2.8% NPR 0.640 +3.2% QZM 0.380 +0.0% BVA 0.750 −1.3% ONAU 0.530 +1.9% FMR 0.225 +0.0% GSVR 0.350 +2.9% PHNM 0.345 +1.5% SLG 5.63 −1.4% CASA 0.065 +8.3% DRY 0.220 +2.3% SOMA 0.580 +3.6% GOLD 4186.90 +0.4% SILVER 57.40 +0.4% COPPER 6.59 +0.5% OIL 96.85 −1.1% PALLADIUM 1120.25 −0.7% MON 0.385 −6.1% OMI 0.255 +2.0% BUFF 0.800 +2.6% FEO 0.670 +3.1% LIB 0.700 −2.8% NPR 0.640 +3.2% QZM 0.380 +0.0% BVA 0.750 −1.3% ONAU 0.530 +1.9% FMR 0.225 +0.0% GSVR 0.350 +2.9% PHNM 0.345 +1.5% SLG 5.63 −1.4% CASA 0.065 +8.3% DRY 0.220 +2.3% SOMA 0.580 +3.6%
Earnings

Red Light Holland Reports Second Quarter 2026 Results and Provides Corporate Update

By The Northwire Desk — AI Analysis Dec 01, 2025 · 16:31 TRIP · 0.03 Red Light Holland Corp.
TRIP · Price

Executive Summary

  • Red Light Holland Corp. announced its financial and operational results for the three and six months ended September 30, 2025, reporting a significant decline in revenue and gross profit compared to the prior year period, alongside a widening adjusted EBITDA loss.
  • The company is undergoing strategic operational streamlining, including the suspension of Shiitake mushroom production at its AEM New Brunswick farm and advanced discussions to sell the AEM Ontario (Peterborough) farmland for an estimated $2.5M–$2.6M.
  • Key operational updates include the launch of Health Canada-approved Functional Mushroom Gummies, an expanded partnership with Albertsons/Safeway in the U.S., and a new Bitcoin strategy allocating up to $2 million in assets.

Key Details

  • Financial Performance (Three Months Ended Sept 30, 2025):
    • Total Cash Balance: $10.226M (down from $11.454M as of June 30, 2025).
    • Revenue: $0.754M (down 44.9% from $1.368M in Q2 2025).
    • Gross Profit: $0.327M (down 68.68% from $0.552M in Q2 2025).
    • Adjusted EBITDA Loss: $0.785M (up 61.9% from $0.485M loss in Q2 2025).
    • Total Net Use of Cash: $1.228M (down 8.5% from $1.342M in Q2 2025).
    • Total Assets: $19.018M (down from $20.140M as of June 30, 2025).
  • R&D and Psilocybin Developments:
    • Irvine Labs (FDA-Compliant, DEA-Registered Partner) completed initial potency testing in August 2025, confirming compatibility with medical-grade manufacturing processes.
    • Received a second shipment of 5kg of natural Psilocybin products in November 2025 under existing DEA quota to support expanded R&D, including validation of proprietary dehydration and packaging processes.
    • Collaboration with Arizona State University (Dr. Candace Lewis) on the Psychedelic Genome Project to understand genetic factors influencing psilocybin response.
    • Appointment of Dr. Robin Carhart-Harris as Scientific Advisor.
    • Plans to commit more financial resources to Psilocybin distribution, drug development, and discovery.
  • Operational Changes and Asset Sales:
    • AEM New Brunswick: Suspended Shiitake mushroom production and sales on or about December 15, 2025, due to industry challenges; evaluating options for the facility.
    • AEM Ontario (Peterborough): In advanced discussions to sell 100% of rights to farmland, plans, and permits for an estimated $2.5M–$2.6M; due diligence phase expected soon.
    • Strategic Streamlining: Management is divesting non-core assets, suspending underperforming activities, and simplifying the operating footprint to enhance financial flexibility.
  • Commercial and Product Updates:
    • Albertsons Partnership: Expanded partnership with Albertsons (under Safeway banner) for Happy Caps Mushroom Home Grow Kits in the U.S. retail market.
    • Happy Caps Gummies: Launched Health Canada-approved Functional Mushroom Gummies (NPN #80137179) on Amazon; passed three months of stability tests.
    • RCSS Pilot: Launched pilot programs for Functional mushroom gummies at Real Canadian Superstore (RCSS) in London, with indications of further expansion.
    • SR Wholesale: Netherlands subsidiary continues sales to over 125 retail stores, though facing tourism slowdowns.
    • Mini-Champ: Sales decreased in Q2 2026 in the Netherlands due to consumer spending slowdowns.
  • Bitcoin Strategy:
    • Announced allocation of up to $2 million in Bitcoin-related assets, led by Cryptocurrency Advisor Scott Melker.
    • Excess cash invested in Bitcoin ETFs and private investments, with remaining funds in high-interest savings.

Notable Quotes

  • "Compared to Q2 2025, which was the strongest in our history, this quarter has been focused on taking a disciplined look at our priorities while continuing to execute across the entire business... we remain in a strong financial and operational position, supported by ongoing discipline in cash spending and reduced G&A." — Todd Shapiro, CEO
  • "We continue to evaluate strategic M&A opportunities from a position of strength at a time when many companies across the sector are facing significant financial pressure. As we evolve further into an R&D-driven organization with a solid balance sheet, we're also seeing increasing inbound interest from groups seeking collaboration or access to capital..." — Todd Shapiro, CEO
Read the original news release →

More from Red Light Holland Corp.

Jun 18, 2026 · 09:02

Early-stage preclinical milestone adds to pipeline, but stock has already priced in a +200% run; execution risk remains high.

Other Jun 08, 2026 · 07:31

Red Light Holland's Wholly Owned Subsidiary, Filament Health, Signs Agreement to Supply PEX010 Botanical Psilocybin Drug Candidate for Study at GHU Paris Psychiatrie & Neurosciences in France

Other Jun 04, 2026 · 07:32

Red Light Holland Secures UCSF Supply Deal for PEX010, But Clinical Progress Remains Incremental Amid Dilution Concerns

Other May 25, 2026 · 08:40

Red Light Holland Expands Filament Health Psychedelic Supply Footprint in New Zealand

Other May 14, 2026 · 08:31

Red Light Holland expands its clinical psilocybin network, but mounting share dilution and a transition to pharma leave investors waiting for a clear commercial catalyst.

Production / Operations May 13, 2026 · 09:13

Red Light Holland Consolidates Psychedelic Platform Post-Acquisition Amidst Management Transition

Financings